An ALK mutation test looks for an abnormal change involving the ALK gene in cancer cells. In lung cancer, the important finding is usually an ALK rearrangement or fusion rather than a small inherited mutation. The fusion switches on ALK signaling and helps the tumor grow. Finding it can change treatment because ALK-positive non-small cell lung cancer often responds strongly to oral ALK inhibitors.
Testing is most often performed on tumor tissue from a biopsy or surgery. A blood-based liquid biopsy may be used when tissue is limited, although a negative blood result does not reliably exclude an ALK fusion. Laboratories may use immunohistochemistry, fluorescence in situ hybridization, next-generation sequencing, or a combination of methods. The result must be interpreted with the cancer type, stage, specimen quality, and the exact alteration detected. ALK testing is generally a tumor test; it does not usually indicate an inherited cancer condition.
- A positive ALK result means the tumor contains a clinically important ALK alteration, most often an ALK fusion in non-small cell lung cancer.
- ALK-positive advanced lung cancer is usually treated with an ALK-targeted tyrosine kinase inhibitor, not with chemotherapy alone as the first systemic treatment.
- A negative result may be inconclusive when the sample has too few tumor cells or when only plasma was tested.
- No fasting or medication changes are needed for the molecular test itself, although biopsy preparation depends on the procedure.
- Results commonly take several days to about three weeks, depending on the method, laboratory, and whether repeat testing is required.
Table of Contents
- What the ALK Test Detects
- Who Should Have ALK Testing
- How ALK Testing Is Performed
- How to Read ALK Test Results
- How Results Guide Treatment
- Resistance and Repeat Testing
- Limitations and Questions to Ask
What the ALK Test Detects
The test looks for an abnormality that activates anaplastic lymphoma kinase, usually called ALK. ALK is a receptor tyrosine kinase, a protein that can pass growth signals into a cell. Normal adult lung cells do not depend on continuously active ALK. In an ALK-positive tumor, part of the ALK gene becomes joined to another gene. The most common partner in lung cancer is EML4, but several other partners occur.
This rearrangement creates a fusion gene that produces an always-active signaling protein. The cancer cell can become highly dependent on that signal, which is why an ALK inhibitor may shrink the tumor. The alteration is called a driver because it contributes directly to cancer growth rather than appearing as an unrelated passenger change.
In everyday use, people may say “ALK mutation test,” but a lung cancer report may use more precise terms such as:
- ALK rearrangement detected
- ALK fusion detected
- EML4::ALK fusion detected
- ALK protein overexpression consistent with rearrangement
- ALK positive by immunohistochemistry
These descriptions are not identical, but each may support a diagnosis of ALK-positive lung cancer when produced by a validated test and interpreted by the pathology team. A broad gene fusion test can identify ALK and other actionable fusions in the same specimen.
ALK fusions occur in roughly 3% to 5% of non-small cell lung cancers, especially lung adenocarcinomas. They are more common in people who have never smoked or smoked lightly and in patients diagnosed at a younger age, but those features cannot replace molecular testing. A person with a long smoking history can still have an ALK-positive tumor.
The ALK alteration found in lung cancer is usually somatic, meaning it arose in the tumor and is not present throughout the body. It is therefore different from a germline result found through inherited-cancer testing. Relatives generally do not need testing because a family member’s lung tumor is ALK positive. Rare inherited ALK variants are associated with other conditions, including familial neuroblastoma, but that is a separate clinical situation.
Who Should Have ALK Testing
ALK testing is standard for many people with non-small cell lung cancer because a positive result can determine treatment. Testing is particularly important for nonsquamous cancers, including adenocarcinoma, that are advanced, metastatic, recurrent, or being considered for systemic therapy. Current practice often uses a broad molecular panel rather than ordering ALK alone, since the same tissue can be assessed for EGFR, ROS1, BRAF, KRAS, MET, RET, NTRK, HER2, and other biomarkers.
Testing may also be appropriate in selected squamous or mixed tumors. Examples include a small biopsy in which the full tumor type is uncertain, a person who never smoked, or a younger patient whose clinical features raise concern for an oncogenic driver. Histology and smoking history can guide testing strategy, but they should not be used as absolute exclusion rules when an actionable result remains plausible.
ALK testing now matters in some resected early-stage lung cancers as well. After complete surgery, an ALK result can affect whether adjuvant targeted therapy is considered. In the United States, alectinib is approved after resection for eligible ALK-positive non-small cell lung cancer, based on stage and other clinical criteria. That makes timely testing relevant before postoperative treatment is finalized, not only after metastatic disease develops.
A clinician may order ALK testing at several points:
- At the initial diagnosis of advanced nonsquamous non-small cell lung cancer.
- After surgery, when the pathologic stage suggests adjuvant systemic treatment may be useful.
- At recurrence, if broad molecular testing was not previously completed.
- When a prior result was negative but the specimen was inadequate or the method had limited fusion coverage.
- At progression on an ALK inhibitor, when repeat molecular testing could identify a resistance mechanism.
ALK testing is not a population screening test. It does not detect lung cancer in healthy people, estimate future lung cancer risk, or replace low-dose CT screening for eligible individuals. It is performed after cancer is suspected or diagnosed to characterize the tumor.
The pathology team should protect enough tissue for a solid tumor NGS panel when possible. Sequential single-gene tests can exhaust a small biopsy, delay treatment, and miss other actionable findings. Reflex testing, in which the laboratory starts biomarker testing automatically after a qualifying diagnosis, can shorten the time to a treatment decision.
How ALK Testing Is Performed
ALK can be assessed with several laboratory methods. The best choice depends on specimen size, laboratory expertise, turnaround time, and whether other biomarkers need to be tested at the same time. **Common ALK testing methods**
| Method | What it detects | Main strengths | Important limitations |
|---|---|---|---|
| Immunohistochemistry (IHC) | Abnormal ALK protein expression | Fast, tissue-efficient, and widely validated | Does not identify the fusion partner or exact breakpoint |
| Fluorescence in situ hybridization (FISH) | Physical separation or rearrangement of ALK DNA | Historically established and useful as an orthogonal method | Requires skilled interpretation and may not define the partner |
| DNA-based next-generation sequencing | ALK rearrangements plus many other genomic changes | Broad profiling from one specimen | Some panels have difficulty with large or repetitive introns |
| RNA-based next-generation sequencing | Expressed ALK fusion transcripts | Often sensitive for diverse fusion partners and confirms expression | RNA can degrade in older or poorly handled tissue |
| Plasma cell-free DNA testing | Tumor-derived ALK alterations released into blood | Noninvasive and useful when tissue is unavailable | A negative result cannot exclude an ALK fusion |
IHC uses antibodies to show whether tumor cells contain unusually high levels of ALK protein. Strong, characteristic staining with a validated assay can be sufficient to call a tumor ALK positive. FISH uses fluorescent probes placed on either side of the ALK breakpoint. When the signals separate in enough tumor nuclei, the laboratory reports a rearrangement. A FISH test for gene rearrangements can be useful when results from another method are uncertain.
Next-generation sequencing can test many genes at once. RNA-based sequencing is especially helpful for fusions because it analyzes the transcript made from the joined genes. DNA-based panels can also detect ALK rearrangements, but panel design matters. A report should state the assay used, whether it is validated for fusions, and any limitations.
The preferred specimen is usually formalin-fixed tumor tissue from a core biopsy, surgical resection, or cytology cell block. The pathologist estimates the percentage of tumor cells and may mark an area for dissection. Bone specimens can be difficult if strong acid decalcification damaged DNA and RNA. Older tissue may still work, but quality decreases with poor fixation, prolonged storage, or extensive necrosis.
A liquid biopsy uses a blood sample to analyze circulating tumor DNA. It can provide a rapid option when biopsy is unsafe or tissue is exhausted. Its sensitivity depends on how much tumor DNA reaches the bloodstream. Small tumors, disease limited to the chest, and some brain-only metastases may shed little DNA. For that reason, a negative plasma result should usually be followed by tissue testing when feasible.
The molecular test itself requires no fasting. For a blood draw, the person can generally eat and take regular medicines unless the clinical team gives other instructions. Preparation for bronchoscopy, needle biopsy, or surgery is different and may include fasting, medication review, and temporary changes to blood thinners.
How to Read ALK Test Results
An ALK report should be read as a complete document, not as a single “positive” or “negative” word. The result, specimen type, tumor percentage, method, quality metrics, and interpretive comment all affect confidence.
Positive or detected
A positive result means the laboratory found evidence of an ALK alteration that meets the assay’s validated criteria. In lung adenocarcinoma, a clearly detected ALK fusion is generally considered an actionable driver. The report may name the fusion partner and variant, such as an EML4::ALK transcript, or it may simply report ALK rearrangement.
A positive result does not show the cancer stage, predict exactly how long a treatment will work, or guarantee response. It indicates that ALK-targeted therapy is biologically appropriate and should be considered with the patient’s stage, prior treatments, brain imaging, medical conditions, and preferences.
Negative or not detected
A negative result means the assay did not find a reportable ALK alteration in the tested material. It is most reliable when the specimen contained enough viable tumor, the test had adequate sensitivity, and the method covered relevant fusion types. A technically sound negative result directs the team toward other biomarkers and treatment options.
A negative result is less reassuring when plasma alone was tested, the tumor fraction was low, RNA quality failed, or the assay did not fully assess fusions. The report may recommend testing another specimen. In that situation, “not detected” does not mean “impossible.”
Indeterminate, equivocal, or inadequate
An indeterminate result means the laboratory could not confidently classify the specimen. Reasons include too few tumor cells, poor signal quality, borderline FISH findings, failed sequencing controls, degraded RNA, or discordant results between methods. The next step may be repeat staining, an alternate technique, testing a different tissue block, or obtaining a new sample.
Discordant results require specialist review. For example, ALK IHC may be strongly positive while FISH is negative or borderline. Modern practice may accept a convincing result from a validated method, but the laboratory and treating oncologist should examine assay performance, morphology, and sequencing data. An orthogonal test—one based on a different technical principle—can resolve uncertainty.
Variant details and report language
Fusion variants and partners can influence research questions and sometimes resistance patterns, but the presence of a validated actionable ALK fusion is usually more important for initial treatment than the exact EML4::ALK variant. Reports may also list a variant allele fraction for sequence changes. That number reflects the proportion of analyzed DNA fragments carrying an alteration; it is not the percentage of the body affected and should not be interpreted as inherited risk.
How Results Guide Treatment
A confirmed ALK-positive result can move treatment away from nonspecific systemic therapy toward an oral ALK tyrosine kinase inhibitor. These drugs bind the abnormal kinase and interrupt the growth signal. They can produce high response rates and often control disease in the brain better than older treatments.
For metastatic ALK-positive non-small cell lung cancer, commonly used modern inhibitors include alectinib, brigatinib, and lorlatinib. The exact first treatment varies by country, regulatory approval, guideline, brain involvement, side-effect profile, other illnesses, drug interactions, and access. Crizotinib was the first widely used ALK inhibitor, but newer agents generally provide longer disease control and better central nervous system activity.
Brain control deserves special attention. ALK-positive lung cancer has a meaningful tendency to spread to the brain. Some ALK inhibitors were designed to cross the blood-brain barrier. Baseline brain MRI is therefore often part of staging, and the choice of drug may account for existing brain metastases or the need to reduce future central nervous system progression.
For eligible patients whose ALK-positive tumor was completely removed, adjuvant alectinib may be considered. Adjuvant treatment aims to lower recurrence risk when scans show no remaining visible cancer. It is different from treatment for metastatic disease, and eligibility depends on pathologic stage, tumor size, lymph-node involvement, surgical outcome, and local approvals.
The ALK result should be available before immunotherapy is started whenever the clinical situation permits. Tumors driven by ALK fusions often respond less reliably to single-agent immune checkpoint therapy than smoking-associated lung cancers without actionable drivers, even when PD-L1 expression is high. Treatment sequencing can also affect toxicity. An oncologist should integrate ALK, PD-L1 testing, stage, symptoms, and the full molecular profile rather than relying on one marker in isolation.
Monitoring during ALK inhibitor treatment can include:
- CT or PET/CT imaging at intervals chosen by the oncology team
- Brain MRI when clinically indicated or as part of surveillance
- Liver tests, blood counts, kidney function, cholesterol, triglycerides, and glucose depending on the drug
- Heart rate, electrocardiograms, blood pressure, or lung assessment when relevant
- Review of swelling, muscle pain, vision changes, fatigue, mood, memory, speech, or concentration symptoms
Side effects differ among agents. Alectinib can cause constipation, fatigue, muscle pain, liver enzyme elevations, anemia, slow heart rate, and rare lung inflammation. Brigatinib can cause early pulmonary symptoms, hypertension, elevated creatine phosphokinase, pancreatic enzyme changes, and other effects. Lorlatinib commonly raises cholesterol and triglycerides and can cause edema, weight gain, peripheral neuropathy, and cognitive or mood changes. Many adverse effects can be managed with monitoring, supportive treatment, or dose adjustment; patients should not stop therapy without contacting the oncology team unless emergency care is required.
Resistance and Repeat Testing
ALK inhibitors can control cancer for years, but resistant cells may eventually grow. Resistance does not mean the original test was wrong. Cancer evolves under treatment pressure, and a later sample may contain new alterations that were absent or too rare to detect at diagnosis.
Resistance can remain ALK dependent. The tumor may acquire a second change in the ALK kinase domain that reduces drug binding. Different ALK inhibitors have different activity against these mutations. Resistance can also be ALK independent, meaning the tumor activates another pathway, amplifies another gene, changes cell type, or develops a broader biological escape mechanism.
When disease progresses, the team first studies the pattern. A single growing brain lesion or isolated bone site may be treated locally with surgery or radiation while the same ALK inhibitor continues. Widespread progression may prompt a switch to another systemic treatment. Symptoms, speed of growth, prior drugs, and the location of progression all influence the plan.
Repeat biopsy or a circulating tumor DNA test may identify a resistance mutation. Tissue has the advantage of showing tumor histology and transformations, while plasma can sample DNA from multiple metastatic sites with less procedural risk. A negative plasma test at progression remains limited by tumor shedding and may need tissue confirmation.
Not every detected resistance alteration has an approved matching therapy. Some results mainly support clinical-trial eligibility or explain why a previous drug stopped working. The report should distinguish approved indications from investigational evidence. A molecular tumor board may be useful when several alterations, unusual fusions, or uncommon resistance patterns appear.
Repeat testing is also reasonable if the original test was narrow or performed years earlier. A modern comprehensive genomic profiling test can reassess ALK and search for other actionable changes, although finding an additional alteration does not automatically prove that it drives the current cancer.
Limitations and Questions to Ask
ALK testing is powerful because it can connect a tumor to an effective targeted treatment, but it has technical and clinical limits. The assay examines only the submitted specimen. Tumors can differ between sites and over time, and a tiny biopsy may not represent every cancer cell. A result also depends on tissue handling, tumor content, assay design, and the laboratory’s reporting threshold.
Common sources of confusion include treating a plasma-negative result as definitive, assuming an ALK fusion is inherited, or believing that a positive test guarantees permanent control. Another mistake is starting treatment before the full molecular panel is complete when the patient is stable enough to wait. Because treatment choices can have long-term consequences, the oncology team should review all actionable biomarkers together.
Useful questions for the care team include:
- Was the test performed on tissue, blood, or both?
- Did the assay directly assess RNA fusions, DNA rearrangements, ALK protein, or more than one of these?
- Was the specimen adequate, and what percentage of cells were tumor?
- Is the ALK finding considered actionable for this cancer type and stage?
- Should the result be confirmed with another method?
- Which ALK inhibitors are appropriate, and how do their brain activity and side effects differ?
- Is baseline brain MRI needed?
- What laboratory tests and symptoms will be monitored during treatment?
- Would repeat tissue or plasma testing help if the cancer progresses?
- Could a clinical trial be relevant now or later?
Seek urgent medical attention for severe shortness of breath, chest pain, fainting, new weakness on one side, a seizure, sudden confusion, or other signs of a medical emergency. During treatment, rapidly worsening breathing, fever with respiratory symptoms, severe mood or behavior changes, or symptoms of liver injury should be reported promptly. The oncology team can give drug-specific instructions.
A well-interpreted ALK result is a treatment biomarker, not a standalone diagnosis. Its value comes from combining a reliable laboratory finding with accurate pathology, complete staging, and ongoing clinical assessment.
References
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 (Guideline)
- FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer 2024
- Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases 2024
- Treatment of metastatic ALK-positive non-small cell lung cancer 2024 (Review)
- New advances in understanding the mechanisms and therapeutic strategies of resistance to ALK-targeted therapy in non-small cell lung cancer 2025 (Review)
- CAP/IASLC/AMP Molecular Testing Guideline 2018 (Guideline)
Disclaimer
This information is educational and does not replace advice from an oncologist, pathologist, or genetic professional. ALK results must be interpreted with the tumor type, stage, specimen quality, current approvals, and the person’s overall health. Contact the treating team promptly for new or severe symptoms during cancer treatment.
